Niknafs Alireza, Rezvanfar Mohammadreza, Kamalinejad Mohammad, Latifi Seyed Amirhosein, Almasi-Hashiani Amir, Salehi Mehdi
Traditional and Complementary Medicine Research Center (TCMRC), Arak University of Medical Sciences, Arak, Iran.
Endocrinology and Metabolism Research Center, Department of Internal Medicine, School of Medicine, Arak University of Medical Sciences, Arak, Iran.
Evid Based Complement Alternat Med. 2021 May 20;2021:6631963. doi: 10.1155/2021/6631963. eCollection 2021.
It has been well established in the world that lipid disorders promote the development of atherosclerosis and its clinical consequences. This study aimed to assess the impacts of a Persian medicinal (PM) compound on lipid profile.
From June 21 to October 21, 2020, a randomized double-blind controlled clinical trial was conducted with 74 dyslipidemic patients, who were randomly divided into two equally populated groups: one prescribed with a Persian medicinal herbal compound ( = 37) and a placebo group ( = 37). A Persian herbal medicine including fenugreek, sumac, and purslane is introduced. Biochemical parameters including 12-hour fasting serum levels of total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), very-low-density lipoprotein (VLDL), and triglyceride (TG) were measured before the initiation and after the completion of study protocol.
Percent changes of biochemical parameters include the following: intervention group = cholesterol: 35.22, Tg: 45.91, LDL: 24.81, HDL: 2.05, VLDL: 8.94 and placebo group = cholesterol: 6.94, Tg: -7.3, LDL: 7.37, HDL: 2.88, VLDL: -0.14. The serum levels of total cholesterol (=0.01) and LDL (=0.01) significantly decreased and no increase was recorded in HDL (=0.03) levels over time in the intervention group. Furthermore, between-group analysis showed a statistically significant difference between the intervention and placebo groups in this regard. VLDL (=0.2) and TG (=0.2) levels also decreased, however not significantly.
This study showed that a Persian medicinal herbal compound could be safe and beneficial to decrease the levels of serum cholesterol and LDL in dyslipidemic patients. However, larger long-term studies are recommended to clarify this effect.
脂质紊乱促进动脉粥样硬化的发展及其临床后果，这在全球已得到充分证实。本研究旨在评估一种波斯药物（PM）化合物对血脂谱的影响。
2020年6月21日至10月21日，对74名血脂异常患者进行了一项随机双盲对照临床试验，这些患者被随机分为两组，每组人数相等：一组服用波斯药用草药化合物（n = 37），另一组为安慰剂组（n = 37）。介绍了一种包括葫芦巴、漆树和马齿苋的波斯草药。在研究方案开始前和完成后，测量了包括12小时空腹血清总胆固醇、低密度脂蛋白（LDL）、高密度脂蛋白（HDL）、极低密度脂蛋白（VLDL）和甘油三酯（TG）水平在内的生化参数。
生化参数的百分比变化如下：干预组=胆固醇：35.22，甘油三酯：45.91，低密度脂蛋白：24.81，高密度脂蛋白：2.05，极低密度脂蛋白：8.94；安慰剂组=胆固醇：6.94，甘油三酯：-7.3，低密度脂蛋白：7.37，高密度脂蛋白：2.88，极低密度脂蛋白：-0.14。干预组总胆固醇（P = 0.01）和低密度脂蛋白（P = 0.01）水平随时间显著降低，高密度脂蛋白（P = 0.03）水平未升高。此外，组间分析显示，在这方面干预组和安慰剂组之间存在统计学显著差异。极低密度脂蛋白（P = 0.2）和甘油三酯（P = 0.2）水平也有所下降，但不显著。
本研究表明，一种波斯药用草药化合物可能对降低血脂异常患者的血清胆固醇和低密度脂蛋白水平是安全且有益的。然而，建议进行更大规模的长期研究以阐明这种效果。
